cPARP is increased in melanoma cells in response to the drug combination, with concomitant decrease in levels of the anti-apoptotic Bcl-2 family member, MCL-1 (Supplementary Figure 6), showing that combined leflunomide and selumetinib treatment increases apoptosis in melanoma cells compared with individual drug treatment. Here, BCL2 is linked to melanoma.